Lidocaine Market Share

Global Lidocaine Market Overview

Lidocaine Market Size was valued at USD 0.89 billion in 2023 and is projected to grow from USD 0.94 Billion in 2024 to USD 1.49 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.26% during the forecast period (2024 - 2032).The prevalence of acute and chronic pain issues worldwide, as well as the many advantages of using lidocaine hydrochloride are the key market drivers enhancing the market growth.

Lidocaine Market Trends

• Growing Prevalence of chronic diseases to boost market growth

Globally, the prevalence of chronic illnesses and ailments is rising. These prevalent and expensive long-term health issues are steadily increasing due to population aging and social behavior changes. Individuals are embracing a more sedentary lifestyle as a result of growing urbanization. As a result, there is an increase in sickness cases and obesity rates. According to the World Health Organization, chronic diseases account for over 60% of yearly mortality and 43% of the worldwide disease burden (WHO).

Furthermore, 88 million American adults have prediabetes, according to the Centers for Disease Control and Prevention's (CDC) National Diabetes Statistical Report, 2020, which found that 34.2 million Americans have diabetes. This situation is anticipated to increase the market for lidocaine growth potential during the projected period. While population growth is predicted to be more critical in developing countries, emerging markets won't be much impacted. Chronic disease pressure on healthcare systems has grown to be a significant concern. The use of tobacco, excessive sugar consumption and unhealthful alcohol usage are factors that contribute to oral ailments. According to the World Health Organization, almost 3.5 billion individuals worldwide are afflicted by oral disorders. More than 530 million children are thought to have primary tooth decay, and 2.3 billion adults have permanent tooth decay. Periodontal disorders, oro-dental trauma, oral HIV symptoms, and periodontal diseases make up most of the oral health issues. Oral conditions affect people throughout their lives, causing discomfort, agony, disfigurement, and sometimes death. They represent a significant burden for many nations. It is projected that rising dental care utilization will boost demand for lidocaine. Such accidents generally impact the cervical and spine region leading to critical injuries. Therefore, such medical conditions has enhanced the Lidocaine market CAGR across the globe in recent years.

However, the rise in surgical treatments conducted around the world, including aesthetic, plastic, and dental operations is another factor driving the growth of the Lidocaine market revenue.

Lidocaine Market Segment Insights

Lidocaine Formulation Insights

Based on Formulation, the Lidocaine Market segmentation includes injections, creams, ointments & gels, and others. The ointments & gels segment held the majority share in 2022, contributing to around ~40% of the Lidocaine Market revenue. Analgesics, such as lidocaine ointment, reduce pain by obstructing nerve signals throughout the body. The demand for lidocaine has increased due to its use as an anti-itching and pain reliever for insect bites, minor wounds, burns, skin scrapes, and eczema, which has led to sector revenue growth.

November 2019: For instance, the U.S. Food and Drug Administration (FDA) granted Lidocaine Ointment USP, 5%, by SunGen Pharma approval for an expedited new drug application.

Lidocaine Application Insights

Based on application, the Lidocaine Market segmentation includes dentistry, cardiac arrhythmia, and epilepsy. The Dentistry segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Its hegemonic position is linked to the rising demand for injectable solutions containing lidocaine hydrochloride in dental surgical procedures. This is anticipated to help the market segment grow, along with the increased prevalence of dental issues and chronic and acute pain connected with dental procedures. Hence, rising applications of Dentistry material for Lidocaine positively impact the market growth.

Lidocaine Distribution Channel Insights

Distribution Channel has bifurcated the Lidocaine Market data into Hospital Pharmacies and Retail Pharmacies. The Hospital Pharmacies segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. More client accessibility and fewer operating costs are two reasons for the segment's rise. People increasingly use online distribution channels to purchase medications, wellness products, and virtual treatments. The COVID-19 epidemic has accelerated this change by increasing awareness of virtual treatment among medical professionals and patients.

Figure 2: Lidocaine Market, by Distribution Channel, 2022 & 2030 (USD billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Retail Pharmacies were the fastest-growing segment. During the assessment period, the market expansion will be aided by creating hospital pharmacies in cardiology, neurology, and other conditions in established and emerging nations, increasing the number of hospitals, and adequate reimbursement scenarios.

Lidocaine Regional Insights

The analysis offers market insights for North America, Europe, Asia-Pacific, and the rest of the world, organised by region. The North American lidocaine market, which had a value of USD 0.3664 billion in 2022, is anticipated to increase at a considerable CAGR over the research period. The rising incidence of pain and pain-related illnesses, as well as the rising prevalence of epilepsy, diabetes, and dental procedures in the US, are driving the market in this area. The increasing demand for cosmetic procedures and the rising patient population have propelled the region's market growth.

Further, the significant countries studied in the market report are The U.S., Canada, Germany, the UK, France, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: LIDOCAINE MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Lidocaine market accounts for the second-largest market share due to the growing incidence of diabetic neuropathy. The prevalence of painful diabetic peripheral neuropathy (PDPN) among patients with diabetes ranges from 5.8% to 34% in Europe, according to the National Center for Biotechnology Information (NCBI). According to all reviewed research, the reported prevalence of PDPN in patients with diabetes mellitus in Europe ranged from 0.7% to 34%. Further, the Germany Lidocaine market held the largest market share, and the UK Lidocaine market was the fastest-growing market in the European region.

From 2022 to 2030, the Asia-Pacific lidocaine market is anticipated to experience the fastest CAGR growth. An increase in the number of dental and cosmetic surgeries, improvements in surgical techniques, and rising usage of lidocaine hydrochloride for postoperative pain treatment can all be linked to an increase in the use of lidocaine hydrochloride. Moreover, the China Lidocaine market held the largest market share, and the India Lidocaine market was the fastest-growing market in the Asia-Pacific region.

Lidocaine Key Market Players & Competitive Insights

Major industry competitors are investing a lot of money in R&D to expand their product portfolios, which will fuel further growth for the lidocaine industry. With significant market developments like new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaborations with other businesses, market participants are also undertaking various strategic efforts to expand their global presence. Lidocaine industry must provide affordable options to prosper and remain in a market that is becoming increasingly competitive.

Manufacturing locally to cut operational costs is one of the leading business methods manufacturers use in the global lidocaine industry to benefit consumers and boost the market sector. Some of the biggest advantages for medicine in recent years have come from the lidocaine business. The Lidocaine market major player such as Covestro AG (Germany), Premier Inc.,  and others are working to expand the market demand by investing in research and development activities.

One of the biggest polymer firms in the world is called Covestro. Its operations are on producing advanced polymer materials and creating creative fixes for products utilized in numerous facets of daily life. The primary industries supplied are those in the automobile, building, woodworking, furniture, electrical, electronics, and home appliance sectors. In August 2020, To establish a Composite Application Center (CAC) in Singapore, Covestro AG (Germany) signed an MoU with a consortium of ten businesses and two research institutions. This was done to create complete solutions for advanced composites, like thermoplastic materials.

Also, A healthcare improvement firm called Premier Inc. brings together an alliance of more than 250,000 additional providers and organizations with 4,400 hospitals and health systems in the United States. Premier, a leader in the field, has built one of the largest collections of helpful information, clinical best practices, and techniques for increasing productivity.  In October 2019, With its ProvideGx program, Premier Inc. collaborated with Amphastar Pharmaceuticals, Inc. to offer emergency, pre-filled syringes containing calcium chloride, epinephrine, sodium bicarbonate, atropine sulfate, dextrose, and lidocaine to healthcare professionals.

Key Companies in the Lidocaine market includes

• SCILEX Pharmaceuticals, Inc.


• Hisamitsu Pharmaceutical Co., Inc.


• Jiangsu Tianji Pharmaceutical Co. Ltd.


• SOFMEDICA


• Perkin Elmer


• Medline Industries, Inc.


• SonoScape Medical Corp.


• Pfizer, Inc.


• KARL STORZ.


• Teikoku Pharma USA, Inc.


• Endomed Systems


• Actavis Labs UT Inc.


• Dun & Bradstreet, Inc.


• PENTAX Medical, among others

Lidocaine Industry Developments

August 2022: The FDA granted Scilex Holding Company fast-track status for SP-103, an experimental medicine and device product candidate. A triple-strength, non-aqueous lidocaine topical system without opioids is called SP-103, and it is used to treat acute lower back pain.

April 2022: Mad Rabbit created numbing lotions that could be applied once to eliminate discomfort. The recipe contains 5% lidocaine, a local anesthetic that blocks pain receptors in the skin to numb the region where it is applied.

Lidocaine Market Segmentation

Lidocaine Formulation Outlook

• Injections


• Creams


• Ointments & Gels


• Others

Lidocaine Application Outlook

• Dentistry


• Cardiac Arrhythmia


• Epilepsy

Lidocaine Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies

Lidocaine Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America